Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| SAB Biotherapeutics Inc. | SAB-142 - (SAFEGUARD) | Type 1 Diabetes | Phase 2b | Enrollment Initiation | Intravenous | Endocrinology |
| SAB Biotherapeutics Inc. | SAB-176 | Type A and Type B influenza | Phase 2b | Data Released | Intravenous | Antiviral |
| Sage Therapeutics Inc. | SAGE-217 - MOUNTAIN | Major Depressive Disorder (MDD) | Phase 3 | Withdrawn | oral | Psychiatric |
| Sage Therapeutics Inc. | SAGE-217 | Postpartum depression (PPD) | Phase 3 | Trial Completed | Oral | Psychiatric |
| Sage Therapeutics Inc. | ZULRESSO (brexanolone) - SAGE-547 (202B) | Postpartum Depression (Severe) | Phase 3 | Trial Completed | Intravenous | Psychiatric |
| Sage Therapeutics Inc. | SAGE-547 | SRSE | Phase 3 | Trial Completed | Intravenous | Neurology |
| Sage Therapeutics Inc. | SAGE-217 - (RAINFOREST) | Insomnia | Phase 3 | Withdrawn | Oral | Psychiatric |
| Sage Therapeutics Inc. | SAGE-217 - (SHORELINE) | Major Depressive Disorder (MDD) | Phase 3 | Data Released | oral | Psychiatric |
